)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Laurus Labs
Laurus Labs (LAURUSLABS) investor relations material
Laurus Labs Q2 26/27 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 26/27 earnings summary29 Oct, 2026
Executive summary
Q2 FY27 revenue reached ₹2,206.37 crore, up 33% YoY; H1 revenue was ₹4,232.68 crore, up 31%, with strong CDMO growth and Affordable Medicines momentum.
H1 EBITDA rose 72% to ₹1,406 crore as gross and EBITDA margins expanded to 62.9% and 33.2%; Q2 EBITDA was ₹762 crore at a 34.5% margin.
Financial highlights
Q2 consolidated profit after tax including associate/JV results was ₹436.19 crore, versus ₹194.49 crore YoY; H1 was ₹798.26 crore, versus ₹— [not provided].
Q2 net profit was ₹441 crore, up 126% YoY; H1 net profit was ₹809 crore, up 126% YoY.
H1 gross margin was 62.9% versus 59.6%; Q2 gross margin was 63.0% versus 59.9% YoY.
Q2 EBITDA was ₹762 crore, up 78% YoY; H1 EBITDA was ₹1,406 crore versus ₹818 crore.
Q2 consolidated basic EPS was ₹8.17; H1 consolidated basic EPS was ₹8.16.
Outlook and guidance
Guidance remains gross margin above 60% and EBITDA margin above 30%; no further revenue or margin forecasts were provided.
Planned FY27–FY28 investment exceeds ₹3,000 crore, with over 85% directed to growth projects; investment near ₹1,500 crore annually after FY28 remains subject to opportunities.
LB-4 fermentation unit capacity exceeds 400 kL and is scheduled for commissioning in Q3 FY27; commercial supplies may begin in Q1 FY28 after trials in Q4 FY27.
KRKA Phase I production blocks are targeted to open in mid-2027; validations are scheduled to start then, with meaningful revenues expected in 2028–2029.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Laurus Labs
- Strong financials, strategic growth, and robust governance drive future confidence.LAURUSLABS
AGM 2026 - Record revenue and profit growth, led by CDMO and generics, with margins and EPS surging.LAURUSLABSQ1 26/27
- FY26 saw 23% revenue and 148% profit growth, with strong CDMO and generics momentum.LAURUSLABSQ4 25/26
- 9M FY26 revenue up 30% and net profit up 388%, led by generics and CDMO growth.LAURUSLABSQ3 25/26
- 33–35% revenue growth, 985% net profit surge, margin expansion, and interim dividend declared.LAURUSLABSQ2 25/26
- Flat revenue, margin pressure, lower profit, but H2 growth and dividend expected.LAURUSLABSQ2 24/25
- Q1 FY25 revenue rose 1% YoY, gross margin hit 55.1%, and a new Independent Director was appointed.LAURUSLABSQ1 24/25
- Strong FY2025 revenue and profit growth, led by CDMO expansion and margin gains, with positive FY2026 outlook.LAURUSLABSQ4 24/25
- Q3 FY25 revenue and profit surged on CDMO and FDF strength, with major investments fueling growth.LAURUSLABSQ3 24/25
Next Laurus Labs earnings date
Q3 26/2722 Jan, 2027
Laurus Labs
Next Laurus Labs earnings date
Q3 26/2722 Jan, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Laurus Labs Limited, a pharmaceutical company, develops, manufactures, and sells active pharmaceutical ingredients (APIs) and formulations in India. It involves in the development of antiviral APIs; generic APIs for hepatitis C and HIV Darunavir tablets; and oncology BCS class II drugs. The company also develops and commercializes single super specialty products comprising linezolid and formoterol. The company was incorporated in 2005 and is based in Hyderabad, India.